PPT-Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC

SWEET Trial Switch to Efavirenz TDFFTC SWEET Study Design Source Fisher M et al J Acquir Immune Defic Syndr 2009515628 Background Randomized controlled openlabel phase 3 trial evaluating a simplification strategy for patients suppressed . Green wire is not connected to ground Connect green wire to ground Ground is required for the sensor switch to function Models MSOPS2 MSVPS2 MSOPS5M MSVPS5M MSOPS6M2DV MSVPS6M2DV White wire is not connected to neutral Connect white wire to neutral N GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . Access and Rational Use. Blood, Radiological and Pharmaceutical Services. Regulatory System Strengthening. Systems approach/ Across all technologies. Contemplate the specificities off specific technologies. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Nithya Srinivas. 1. , John Fallon. 1. , Craig Sykes. 1. , Nicole White. 1. , Amanda Schauer. 1. , Lou Adamson. 2. , Michelle Matthews. 1. , Paul Luciw. 2. , Phil Smith. 1. , Angela DM Kashuba. 1. 1. University of North Carolina at Chapel Hill, Chapel Hill, United States, . stop using your credit cards - switch to MOVO to spend just what you have budgeted for the month APM Resident Education Curriculum. Karina . Uldall. MD, MPH . Inpatient Psychiatry and Psychosomatic Medicine . Section Head, Virginia Mason Hospital Psychiatry Consultation Service. Updated. Fall 2013. . SSAT-029 STUDY . Switch to Etravirine from Efavirenz Due to CNS Toxicity . SSAT-029: Design. Source: Waters L, et al. . AIDS. 2011;25:65-71.. Immediate. . Switch Arm. Etravirine. + 2NRTI. (n = 20). Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. A nested analysis of the Swear randomized multicenter open-label controlled trial. Giuseppe Lapadula. 1*. , . Elena Bresciani. 2. , Irene Baldisserotto. 2. , Francesca Bai. 3. , Emanuele Focà. 4. Canadian Study. CHEER. Montreal Study. EASIER. SWITCHMRK. SPIRAL. Switch ER. Design. Endpoints. Primary: non inferiority in the proportion of patients with treatment failure at W48* (non completer = failure, intent-to-treat analysis), lower . ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm .